Skip to content

Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection

Study of the Physiology of Pre-eclampsia and Vascular Intrauterine Growth Restriction With Constitution of a Biological Collection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03626233
Acronym
CPVP
Enrollment
500
Registered
2018-08-10
Start date
2018-08-06
Completion date
2028-08-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Eclampsia

Brief summary

Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal

Interventions

OTHERcollect of placenta, blood and urinary samples at delivery

collect of placenta, blood and urinary samples at delivery

Sponsors

Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* pregnant women * With or without vascular pathology

Exclusion criteria

* refusal to participate * multiple pregnancy * major fetal malformation diagnosed during pregnancy follow-up

Design outcomes

Primary

MeasureTime frameDescription
genomic analysis on placentaday of deliveryby chromatin immunoprecipitation-sequencing (ChIP-seq)

Secondary

MeasureTime frameDescription
genomic analysis on bloodday of deliveryby ChIP-seq
genomic analysis on placentaday of deliveryby immunohistochemistry an polymerase chain-reaction
VEGF blood levelday of delivery
PLGF blood levelday of delivery
sFlt1 blood levelday of delivery
sKDR blood levelday of delivery

Countries

France

Contacts

CONTACTDiane REDEL
diane.redel@chicreteil.fr145175530
CONTACTcamille Jung
camille.jung@chicreteil.fr157022268
PRINCIPAL_INVESTIGATOREdouard Lecarpentier, MD PhD

CHI CRETEIL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026